#4 - Bristol-Myers Squibb (NYSE:BMY)
Growth investors getting involved in the biopharmaceutical space have been flocking to companies manufacturing GLP-1 weight-loss drugs. But value investors looking to get involved in this sector should look at The Bristol-Myers Squibb Company (NYSE: BMY). The stock hasn’t been a great hold over the last 10 years, with a total return of 21.8%.
The company’s lead products — Revlimid (multiple myeloma) and Eliquis (blood thinner) — continue to deliver year-over-year growth to the company’s top line. Plus, Bristol-Myers has a deep pipeline, particularly with neurodegenerative drugs including a candidate in clinical-stage trials for treating Alzheimer’s Disease, that are likely to add long-term growth for investors.
BMY stock is attractively valued at around 13x forward earnings and has over $6 billion in cash on its balance sheet. Nevertheless, analysts are neutral to slightly bearish on the stock. But after an earnings report in which it beat on the top and bottom lines, analysts may change their outlook. And even if they don’t, you’ll benefit from a growing dividend with a yield of 4.37%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More - Current Price
- $57.33
- Consensus Rating
- Hold
- Ratings Breakdown
- 5 Buy Ratings, 13 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $55.64 (2.9% Downside)
